Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Athira Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ATHA
Nasdaq
8731
https://www.athira.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Athira Pharma Inc
One Athira Pharma Insider Raised Their Stake In The Previous Year
- Apr 23rd, 2024 1:28 pm
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
- Apr 15th, 2024 11:00 am
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
- Apr 11th, 2024 11:00 am
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
- Apr 3rd, 2024 11:00 am
Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?
- Mar 29th, 2024 1:40 pm
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
- Mar 8th, 2024 12:00 pm
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
- Mar 1st, 2024 2:40 pm
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy?
- Feb 28th, 2024 5:00 pm
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
- Feb 22nd, 2024 9:05 pm
2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)
- Feb 15th, 2024 7:56 pm
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
- Feb 8th, 2024 9:02 pm
With 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investors
- Jan 22nd, 2024 10:55 am
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
- Jan 8th, 2024 12:00 pm
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
- Jan 3rd, 2024 12:00 pm
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?
- Dec 26th, 2023 10:07 am
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
- Dec 12th, 2023 12:00 pm
Sidoti Events, LLC's Virtual December Small-Cap Conference
- Dec 5th, 2023 3:25 pm
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
- Nov 29th, 2023 12:00 pm
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
- Nov 28th, 2023 12:00 pm
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
- Nov 15th, 2023 1:15 pm
Scroll